SonoThera closes $125M Series B for next-generation genetic medicines
SonoThera’s $125 million Series B is a strong biotech funding signal for next-generation genetic medicines in a more selective capital market.
Biotech funding is still selective, but strong platform stories can attract serious capital. SonoThera’s new round shows investor appetite for genetic medicine remains alive when the science and market opportunity are compelling.
What happened
SonoThera closed an oversubscribed $125 million Series B to advance its work on next-generation genetic medicines. The company is developing approaches aimed at treating disease at its underlying biological causes.
Why it matters
Genetic medicines can be powerful, but they are technically difficult, capital-intensive and slow to develop. A round of this size gives SonoThera more room to advance its platform and pipeline through the next stages of development.
The bigger picture
Life sciences investing is increasingly focused on platforms that can support multiple therapies, not just one asset. Companies that can improve delivery, precision and scalability may shape the next wave of genetic medicine.